Scott Tagawa, MD, on Data Regarding Treatment Patterns and Survival for Metastatic Castration-Sensitive Prostate Cancer


Scott Tagawa, MD, spoke about the implications of the results from his research on treatment patterns of patients with metastatic castration-sensitive prostate cancer, as well as the need for further studies with other data sets.

CancerNetwork® spoke with Scott T. Tagawa, MD, MS, a professor of medicine at Weill Cornell Medicine and physician at NewYork-Presbyterian – Weill Cornell Medical Center, at the 2021 European Society for Medical Oncology (ESMO) Congress about his research into treatment patterns and overall survival in patients with metastatic castration-sensitive prostate cancer from 2006 to 2019.

Of note, although only 20% of patients with metastatic castration-sensitive prostate cancer in this research received intensified therapy, there was a general improvement to length of life. Tagawa suggests intensified therapy, which he described as the most appropriate therapy for the average patient with this disease, should be given to more than just a minority of patients.


This and other population-based or claim-based big databases look at hundreds or thousands of patients up through 2019, even 2020 in the post charted landscape, [and those receiving intensified therapy are] still in the minority of patients. Maybe up to 50%, but a huge chunk of patients are receiving either [androgen deprivation therapy; ADT] alone or ADT plus an old-fashioned nonsteroidal antiandrogen as their frontline therapy. This is despite approximately a 40% improvement in overall survival with those novel drugs being used earlier rather than saved for later. We need to do [more research], not just in this Veterans Health Administration, but in other data sets [including] Medicare and some different commercial insurance plans. I think we need more research into why that’s happening and more education or a combination of both. Providers as well as patients [need assistance] to figure out why patients are not getting the optimal therapy.


Freedland SJ, Sandin R, Tagawa ST, et al. Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019. Ann Oncol. 2021;32(suppl 5):609P. doi:10.1016/j.annonc.2021.08.1122

Related Videos
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
Related Content